Stiefel (nine products) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

Stiefel (nine products) General Information

Description

Stiefel, a GlaxoSmithKline company, sold off nine dermatology products to Renaissance Pharma. Renaissance Pharma was given the rights to manufacture, market and sell all nine products. These products from GSK and Stiefel, which will be marketed through Renaissance's branded division Prestium Pharma ("Prestium"), include: 1. Evoclin® (clindamycin phosphate) Foam, 1% 2. Extina® (ketoconazole) Foam, 2% 3. Luxiq® (betamethasone valerate) Foam, 0.12% 4. Olux® (clobetasol propionate) Foam, 0.05% 5. Olux-E® (clobetasol propionate) Foam, 0.05% 6. Vusion® (miconazole nitrate 0.25%, zinc oxide 15% and white petrolatum 81.35%) Ointment 7. Zovirax® (acyclovir) Capsules 8. Zovirax® (acyclovir) Tablets 9. Zovirax® (acyclovir) Suspension

Contact Information

Website
www.stiefel.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Medical Supplies
Primary Office
  • 20 T.W. Alexander Drive
  • Durham, NC 27709
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Stiefel (nine products) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Stiefel (nine products)‘s full profile, request access.

Request a free trial

Stiefel (nine products) Executive Team (1)

Name Title Board Seat Contact Info
Simon Jose President
To view Stiefel (nine products)’s complete executive team members history, request access »

Stiefel (nine products) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Stiefel (nine products)‘s full profile, request access.

Request a free trial